Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma

References

• Takatsuki F, Yamaguchi K, Hattori T. Adult T-cell leukemia/lymphoma. Retrovirus Biology and Human Disease, R C Gallo, F Wong-Staal. Marcel Dekker, New York 1990; 147–159
   Google Scholar
• Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka T, et al. Antibodies to adult T-cell leukemia-virus – associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nationwide sero-epidemiologic study. Int J Cancer 1982; 29: 631–635
   PubMed Web of Science ®Google Scholar
• Gessain A, Barin F, Vernant J C, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407–410
   PubMed Web of Science ®Google Scholar
• Kaplan J E, Khabbaz R F. The epidemiology of human T-lymphotropic virus type I and II. Med Virol 1993; 3: 137–148
   Web of Science ®Google Scholar
• Gessain A. Epidemiology of HTLV-I and associated diseases. Human T-Cell Lymphotropic Virus Type 1, P Höllsberg, D A Hafler. John Wiley, New York 1996; 33–64
   Google Scholar
• Safai B, Huang J L, Boeri E, Farid R, Raafat J, Schutzer P, et al. Prevalence of HTLV type I infection in Iran: a serological and genetic study. AIDS Res Hum Retroviruses 1996; 12: 1185–1190
   PubMed Web of Science ®Google Scholar
• Abbaszadegan M R, Gholamin M, Tabatabaee A, Farid R, Houshmand M, Abbaszadegan M. Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J Clin Microbiol 2003; 41: 2593–2595
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Gimbrone M, Leapman S, Cotran R, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261–276
   PubMed Web of Science ®Google Scholar
• Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58–61
   PubMed Web of Science ®Google Scholar
• Friesel R E, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9: 919–925
   PubMed Web of Science ®Google Scholar
• Otrock Z K, Makarem J A, Shamseddine A I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 38: 258–268
   PubMed Web of Science ®Google Scholar
• El-Sabban M E, Merhi R A, Haidar H A, Arnulf B, Khoury H, Basbous J, et al. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood 2002; 99: 3383–3389
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Abou Merhi R, Gessain A, Talhouk R, El-Khoury H, Nasr R, et al. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Res 2004; 64: 2039–2046
   PubMed Web of Science ®Google Scholar
• Kchour G, Makhoul N J, Mahmoudi M, Kooshyar M M, Shirdel A, Rastin M, et al. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma 2007; 48: 330–336
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984 – 87). Br J Haematol 1991; 79: 428–437
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064–3073
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non Hodgkin's lymphomas: an immunohistochemical and structural study. Eur J Haematol 1996; 56: 45–53
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999; 94: 3334–3339
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712–3718
   PubMed Web of Science ®Google Scholar
• Ganjoo K N, An C S, Robertson M J, Gordon L I, Sen J A, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998–1005
   PubMed Web of Science ®Google Scholar
• Perez-Atayde A R, Sallan S E, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815–821
   PubMed Web of Science ®Google Scholar
• Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637–2644
   PubMed Web of Science ®Google Scholar
• Hussong J W, Rodgers G M, Shami P J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309–313
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245
   PubMed Web of Science ®Google Scholar
• Chen H, Treweeke A T, West D C, Till K J, Cawley J C, Zuzel M, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96: 3181–3187
   PubMed Web of Science ®Google Scholar
• Kini A R, Kay N E, Peterson L C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000; 14: 1414–1418
   PubMed Web of Science ®Google Scholar
• Zahiragic L, Schliemann C, Bieker R, Thoennissen N H, Burow K, Kramer C, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007; 21: 1310–1312
   PubMed Web of Science ®Google Scholar